Content Spotlight
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
To support their COVID-19 vaccine candidates, Novavax has secured space at Endo’s facility and Johnson & Johnson has struck a deal with Grand River Aseptic Manufacturing (GRAM).
As Novavax progresses its COVID-19 vaccine candidate through the clinic, the firm has inked numerous deals with contract development and manufacturing organizations (CDMOs) to ensure it will be ready for large-scale production.
The latest focuses on the fill and finish of the Phase II candidate, NVX-CoV2373, with a deal in place with Par Sterile Products – a subsidiary of Endo International.
Image: iStock/wellesenterprises
NVX-CoV2373 is a potential vaccine against the COVID-19 consisting of a prefusion protein made using Novavax’ nanoparticle technology based on infecting Sf9 insect cells with baculovirus viral vectors that express the SARS-CoV-2 spike protein. The vaccine is also being tested with Novavax’ Matrix M adjuvant, a saponin-based adjuvant that acts in part by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in the local lymph nodes.
Par Sterile’s facility in Rochester, Michigan will initially make batches for a Phase III trial but will then fill-finish the NVX-CoV2373 vaccine for commercial distribution in the US, if the candidate is approved.
“Our Rochester, Michigan facility has a long history of manufacturing critical vaccines and sterile injectable products for the US market and we are proud to partner with Novavax on such a critical initiative,” said Blaise Coleman, CEO of Endo. “This partnership further underscores Endo’s commitment to helping everyone we serve live their best life through the delivery of life-enhancing therapies”
Meanwhile, Johnson & Johnson, which recently initiated a Phase III trial for its recombinant protein candidate Ad26.COV2-S, has secured fill and finish capabilities at Grand Rapids, Michigan-based Grand River Aseptic Manufacturing (GRAM).
“The agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson’s SARS-CoV-2 vaccine candidate,” the CDMO said in a statement. “Together, teams from both companies are working diligently to transfer the manufacturing process to GRAM’s new, state-of-the-art facility, and are swiftly preparing for the start of vaccine production.”
The new GRAM facility opened in July and represents a $60 million recent expansion, which tripled the CDMO’s footprint.
You May Also Like